Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202790291> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3202790291 endingPage "270" @default.
- W3202790291 startingPage "263" @default.
- W3202790291 abstract "The aim of the study was to describe the role of hormonal therapy in the treatment of malignant uterine tumors, indications, the effect of the treatment and to verify its safety in our study cohort. We also present an overview of recent studies on that topic.Unicentric retrospective observational study and review of recent literature.Department of Obstetrics and Gynecology, Masaryk University, University Hospital Brno.The results of recent relevant studies and reviews published in English until December 2017 were used for the review. The publications were searched using the PubMed server. All patients diagnosed in our oncogynecological center between 2010 and 2016 and who were treated hormonally - either in primary therapy or in relapse settings, were included in our study. We were interested in age, BMI, stage of disease, histological type and grade of tumor, occurrence of adverse effects, duration of survival, reasons for choosing hormonal therapy. Medroxyprogesterone-acetate or megestrol-acetate was used in the treatment.Between 2010 and 2016, 415 malignant tumors of the uterus were diagnosed in our oncology center. Recurrence of the disease occurred in 31 patients (8%), on average 16 months after primary treatment. Primary hormonal therapy was used in only 19 patients (5%), mostly because of contraindications of another treatment due to high age, comorbidities or obesity. Median age of patients was 83 years, mean BMI 41, median survival of patients who died was 8 months. Five patients (16%) were treated hormonally for the recurrence. Median survival from diagnosis of recurrence was 20 months. One patient (4%) experienced partial pulmonary embolism.Hormonal therapy plays an irreplaceable role in uterine cancer patients, especially in primary non-operable patients, in treatment of a relapse, or in a fertility-sparing procedure. This treatment option is safe, with minimal adverse effects." @default.
- W3202790291 created "2021-10-11" @default.
- W3202790291 creator A5001671621 @default.
- W3202790291 creator A5016823827 @default.
- W3202790291 creator A5029568972 @default.
- W3202790291 creator A5047066500 @default.
- W3202790291 creator A5047935391 @default.
- W3202790291 creator A5051467892 @default.
- W3202790291 creator A5051631099 @default.
- W3202790291 creator A5053569505 @default.
- W3202790291 creator A5069036216 @default.
- W3202790291 creator A5084932449 @default.
- W3202790291 date "2018-11-18" @default.
- W3202790291 modified "2023-10-18" @default.
- W3202790291 title "The role of hormonal therapy in patients with uterine carcinoma." @default.
- W3202790291 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30441956" @default.
- W3202790291 hasPublicationYear "2018" @default.
- W3202790291 type Work @default.
- W3202790291 sameAs 3202790291 @default.
- W3202790291 citedByCount "0" @default.
- W3202790291 crossrefType "journal-article" @default.
- W3202790291 hasAuthorship W3202790291A5001671621 @default.
- W3202790291 hasAuthorship W3202790291A5016823827 @default.
- W3202790291 hasAuthorship W3202790291A5029568972 @default.
- W3202790291 hasAuthorship W3202790291A5047066500 @default.
- W3202790291 hasAuthorship W3202790291A5047935391 @default.
- W3202790291 hasAuthorship W3202790291A5051467892 @default.
- W3202790291 hasAuthorship W3202790291A5051631099 @default.
- W3202790291 hasAuthorship W3202790291A5053569505 @default.
- W3202790291 hasAuthorship W3202790291A5069036216 @default.
- W3202790291 hasAuthorship W3202790291A5084932449 @default.
- W3202790291 hasConcept C121608353 @default.
- W3202790291 hasConcept C126322002 @default.
- W3202790291 hasConcept C167135981 @default.
- W3202790291 hasConcept C2776306185 @default.
- W3202790291 hasConcept C2778311097 @default.
- W3202790291 hasConcept C2779134260 @default.
- W3202790291 hasConcept C2780275930 @default.
- W3202790291 hasConcept C29456083 @default.
- W3202790291 hasConcept C530470458 @default.
- W3202790291 hasConcept C71315377 @default.
- W3202790291 hasConcept C71924100 @default.
- W3202790291 hasConceptScore W3202790291C121608353 @default.
- W3202790291 hasConceptScore W3202790291C126322002 @default.
- W3202790291 hasConceptScore W3202790291C167135981 @default.
- W3202790291 hasConceptScore W3202790291C2776306185 @default.
- W3202790291 hasConceptScore W3202790291C2778311097 @default.
- W3202790291 hasConceptScore W3202790291C2779134260 @default.
- W3202790291 hasConceptScore W3202790291C2780275930 @default.
- W3202790291 hasConceptScore W3202790291C29456083 @default.
- W3202790291 hasConceptScore W3202790291C530470458 @default.
- W3202790291 hasConceptScore W3202790291C71315377 @default.
- W3202790291 hasConceptScore W3202790291C71924100 @default.
- W3202790291 hasIssue "4" @default.
- W3202790291 hasLocation W32027902911 @default.
- W3202790291 hasOpenAccess W3202790291 @default.
- W3202790291 hasPrimaryLocation W32027902911 @default.
- W3202790291 hasRelatedWork W2019647253 @default.
- W3202790291 hasRelatedWork W2047111383 @default.
- W3202790291 hasRelatedWork W2067208421 @default.
- W3202790291 hasRelatedWork W2093111077 @default.
- W3202790291 hasRelatedWork W2111166170 @default.
- W3202790291 hasRelatedWork W2275054999 @default.
- W3202790291 hasRelatedWork W2288654653 @default.
- W3202790291 hasRelatedWork W2412651914 @default.
- W3202790291 hasRelatedWork W2790136985 @default.
- W3202790291 hasRelatedWork W4241306232 @default.
- W3202790291 hasVolume "83" @default.
- W3202790291 isParatext "false" @default.
- W3202790291 isRetracted "false" @default.
- W3202790291 magId "3202790291" @default.
- W3202790291 workType "article" @default.